Buoyed by better-than-expected corporate earnings, U.S. stocks demonstrated strong upward momentum this week, with the S&P 500 index nearing its all-time high of 6,400 points. Market confidence has doubled as over 80% of listed companies reported positive earnings surprises, supported by stable economic indicators and subdued VIX volatility readings.

The bullish trend has been further reinforced by progress in U.S.-China trade negotiations and a strengthening dollar index. Investors are now awaiting the Federal Reserve's upcoming rate decision meeting and employment report, with widespread expectations that policymakers will maintain current rates while potentially signaling future cuts.

Microsoft Cybersecurity Crisis Emerges

Behind this optimistic market backdrop, Microsoft faces growing cybersecurity challenges. Recent reports reveal that the company's Security Vulnerability Alert Program (MAPP) may have suffered internal information leaks, enabling Chinese hackers to exploit SharePoint vulnerabilities affecting more than 400 global organizations—including the U.S. National Nuclear Security Administration.

Microsoft has attributed the attacks to the China-state-sponsored hacking group "Linen Typhoon" , alleging they exploited weaknesses in the MAPP system. While designed to help security firms prepare defenses in advance, the MAPP program has long faced scrutiny over potential information leaks through Chinese partner companies. Chinese authorities have vehemently denied the allegations, reiterating their opposition to all forms of cyberattacks.

Cybersecurity experts are calling for enhanced transparency and oversight of information flows to prevent similar incidents, as the breach highlights systemic vulnerabilities in global digital infrastructure.

Eli Lilly's Alzheimer's Drug Gains EU Support

In pharmaceutical developments, Eli Lilly's Alzheimer's treatment Kisunla received positive evaluation from European Medicines Agency experts, positioning it to become the region's second approved drug to slow cognitive decline. The therapy targets specific genetic profiles while demonstrating lower risks of brain swelling compared to alternatives.

Market analysts project Kisunla could achieve $2 billion in annual sales by 2030, citing its convenient monthly injection regimen. However, the drug's effectiveness appears limited to early-stage patients, and concerns remain about potential neurological side effects. The approval sets the stage for intensified competition with Eisai's rival treatment in the evolving Alzheimer's therapeutics market.